Antidepressants: World Prescription Drug Markets

1 Executive Summary
1.1 Scope and Objectives of Report
1.2 Methodology

2 Overview
2.1 Depression Definitions
2.1.1 Major Depressive Disorder
2.1.2 Dysthymic Disorder
2.1.3 Bipolar Disorders
2.1.4 Cyclothymic Disorder
2.1.5 Seasonal Affective Disorder
2.1.6 Postnatal Depression
2.1.7 Premenstrual Dysphoric Disorder
2.1.8 Depression-related Indications
2.2 Pathology and Diagnosis of Depression
2.1.1 Pathogenesis of Depression
2.1.2 Diagnosis of Depression
2.3 Epidemiology
2.3.1 Global Depression Patient Populations
2.3.2 Prevalence of Depression
2.3.3 Prevalence of Comorbid Disease
2.4 Economic Disease Burden

3 Prescription Antidepressants on the Market
3.1 Overview of Antidepressants
3.1.1 Major Prescription Drug Classes
3.2 Monoamine Oxidase Inhibitors (MAOIs)
3.3 Tricyclic Antidepressants (TCAs)
3.4 Selective Serotonin Reuptake Inhibitors (SSRIs)
3.4.1 Fluoxetine
3.4.2 Citalopram
3.4.3 Paroxetine
3.4.4 Sertraline
3.4.5 Fluvoxamine
3.4.6 Escitalopram
3.5 Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
3.5.1 Venlafaxine
3.5.2 Nefazodone
3.6 Other Antidepressants
3.6.1 Mirtazapine
3.6.2 Bupropion
3.6.3 Reboxetine
3.6.4 Trazodone
3.7 Current Treatment Costs
3.7.1 Comparative Treatment Costs
3.7.2 Comparative Regional Costs

4 Antidepressants in Development
4.1 Unmet Needs
4.2 Novel Serotonergics
4.2.1 Gepirone-ER
4.2.2 OFC (olanzapine/fluoxetine)
4.2.3 S-20098 (agomelatine)
4.2.4 Sunepitron
4.2.5 AR-A000002
4.2.6 DU-125530
4.2.7 Ectis (filbanserin)
4.2.8 Elzasonan
4.2.9 Eplivanserine
4.2.10 Eptapirone
4.2.11 MKC-242
4.2.12 NAD-299 (robalzotan)
4.2.13 OPC-14523
4.2.14 ORG 12962
4.2.15 YKP10A
4.2.16 YM-992
4.2.17 S-20499 (alnespirone)
4.2.18 Vilazodone (SB659746A)
4.3 Novel Noradrenergics
4.3.1 Cymbalta (duloxetine)
4.3.2 (R)-sibutramine
4.3.3 MCI-225
4.3.4 NS-2389
4.4 Neurokinin Antagonists
4.4.1 CP-122,721
4.4.2 Emend (aprepitant)
4.4.3 GW-597599
4.4.4 R673
4.4.5 SR 142801 (osanetant)
4.4.6 SR 48968 (saredutant)
4.4.7 TAK-637
4.5 Other Novel Antidepressants
4.5.1 ORG 34517
4.5.2 SR 58611
4.5.3 INN-835 (nemifitide)
4.5.4 KW-6002
4.5.5 EmSam (selegiline)
4.5.6 Befloxatone
4.5.7 Igmesine
4.6 New Indications and Reformulations of Current Therapies
4.6.1 Bupropion
4.6.2 Sertraline
4.6.3 Venlafaxine
4.6.4 Escitalopram
4.6.5 Fluvoxamine
4.6.6 Paroxetine
4.6.7 Nefazodone

5 World Market Analysis
5.1 Total Global Market Sizes and Projections, 2001-2007
5.2 Historical Market Sizes, 2001-2002
5.2.1 By Drug Class
5.2.2 By Geographic Region
5.3 Market Sizes and Projections by Drug Class, 2001-2007
5.3.1 SSRIs and Novel Serotonergics
5.3.2 SNRIs and Novel Noradrenergics
5.3.3 Neurokinin Antagonists
5.3.4 Tricyclics and MAOIs
5.3.5 Other Antidepressants
5.4 Market Sizes and Projections by Leading Drugs, 2003-2007
5.4.1 Market Forecasts of Current Antidepressant Drugs
5.4.2 Market Forecasts of Drugs in Development
5.5 Historical Market Sizes by Competitor, 2001-2002

6 Market Trends and Opportunities
6.1 Market Trends
6.1.1 Mega Brands
6.1.2 Patent Expiries
6.1.3 Alternatives to Traditional SSRIs
6.1.4 Cost Containment
6.2 Market Growth Drivers
6.2.1 Growing Patient Base
6.2.2 Direct-to-Consumer Marketing
6.2.3 Novel Indications
6.2.4 New Drug Formulations
6.2.5 New Modes of Action
6.3 Market Opportunities
6.3.1 Brand Differentiation
6.3.2 Technology Differentiation
6.3.3 Indication Differentiation

7 Company Briefs
7.1 AstraZeneca
7.2 Bristol-Myers Squibb
7.3 Eli Lilly
7.4 Forest Laboratories
7.5 GlaxoSmithKline
7.6 H. Lundbeck
7.7 Merck & Co.
7.8 Organon International
7.9 Pfizer
7.10 Sanofi-Synthelabo
7.11 Solvay
7.12 Wyeth